Published in Brain Res on February 16, 2008
Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science (2011) 3.48
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.37
A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep (2012) 1.22
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci (2012) 1.15
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol (2009) 1.08
Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology (2010) 1.07
Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast (2011) 1.06
Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem (2010) 1.05
Immunotherapy for Alzheimer's disease. Biochem Pharmacol (2014) 1.04
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol (2009) 1.02
Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol (2009) 1.02
Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol Appl Neurobiol (2010) 1.02
Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J Biol Chem (2011) 0.97
Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging (2010) 0.97
Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha). Endocrinology (2009) 0.96
An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol (2013) 0.95
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct (2009) 0.95
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 0.95
Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol (2011) 0.94
Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem (2010) 0.93
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
Molecular dynamics simulations of Ibuprofen binding to Abeta peptides. Biophys J (2009) 0.91
Combination therapy in a transgenic model of Alzheimer's disease. Exp Neurol (2013) 0.90
Neurogenesis in Alzheimer's disease. J Anat (2011) 0.90
A shortened Barnes maze protocol reveals memory deficits at 4-months of age in the triple-transgenic mouse model of Alzheimer's disease. PLoS One (2013) 0.90
Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Curr Neuropharmacol (2011) 0.89
Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol (2013) 0.89
Age-related changes in core body temperature and activity in triple-transgenic Alzheimer's disease (3xTgAD) mice. Dis Model Mech (2012) 0.87
Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis. US Neurol (2010) 0.86
Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation (2014) 0.85
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol (2014) 0.85
Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol Commun (2014) 0.85
R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease. Brain Res (2013) 0.84
Molecular dynamics simulations of anti-aggregation effect of ibuprofen. Biophys J (2010) 0.83
Calcium and neurogenesis in Alzheimer's disease. Front Neurosci (2010) 0.82
Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models. Curr Pharm Des (2014) 0.81
Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. Brain (2014) 0.81
Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiol Aging (2013) 0.80
The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. Brain Res (2014) 0.80
Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler (2012) 0.80
Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. J Med Chem (2012) 0.79
NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacology (2012) 0.79
NSAIDs may protect against age-related brain atrophy. Front Aging Neurosci (2010) 0.78
Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. Sci Rep (2016) 0.78
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans. Alzheimers Res Ther (2015) 0.77
Thinking outside the box about COX-1 in Alzheimer's disease. Neurobiol Dis (2010) 0.76
A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease. Exp Gerontol (2016) 0.75
Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi (2014) 0.75
AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease. Neurodegener Dis (2016) 0.75
Effects of Ibuprofen on Cognition and NMDA Receptor Subunit Expression Across Aging. Neuroscience (2017) 0.75
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. ACS Chem Neurosci (2016) 0.75
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A (1975) 15.35
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Alzheimer's disease. Lancet (2006) 9.15
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 6.62
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int (2002) 3.10
Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci (1998) 3.03
Molecular pathways to neurodegeneration. Nat Med (2004) 2.94
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res (1997) 2.71
Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci (2004) 2.64
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci (2004) 2.53
Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem (1992) 2.40
Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging (2000) 2.40
Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci (2003) 2.35
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem (1995) 2.24
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem (2001) 2.14
Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med (2004) 2.06
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry (2002) 2.00
Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol (1998) 1.89
Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science (1999) 1.88
Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol (1991) 1.86
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett (2001) 1.82
Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med (2001) 1.82
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science (2003) 1.77
Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem (2006) 1.68
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging (2001) 1.59
Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol (2003) 1.55
Transitive inference in rats (Rattus norvegicus). J Comp Psychol (1992) 1.52
Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid (2002) 1.52
A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem (1997) 1.47
Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation (2006) 1.47
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem (2005) 1.41
Estrogen replacement improves spatial reference memory and increases hippocampal synaptophysin in aged female mice. Neuroscience (2002) 1.38
Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology (2005) 1.28
Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol (2001) 1.25
Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol (2000) 1.17
The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic (2002) 1.14
ADDLs & protofibrils--the missing links? Neurobiol Aging (2002) 1.10
Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci U S A (2000) 1.10
Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am J Pathol (2004) 1.09
Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology (1998) 1.09
Molecular regulation of membrane resealing in 3T3 fibroblasts. J Biol Chem (2004) 1.08
Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol Aging (1998) 1.08
Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann N Y Acad Sci (1996) 1.07
Microtubular reorganization and dendritic growth response in Alzheimer's disease. Ann Neurol (1989) 1.06
Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging (2005) 1.00
Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport (2003) 0.97
Damage to the hippocampal formation in rats selectively impairs the ability to learn cue relationships. Behav Neural Biol (1989) 0.96
The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs (2004) 0.95
The mechanism of action of anti-inflammatory drugs. Int J Clin Pract Suppl (2003) 0.89
Dose-dependent pharmacokinetics of ibuprofen in the rat. Drug Metab Dispos (1987) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease. N Engl J Med (2010) 13.13
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med (2012) 6.27
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci (2007) 5.72
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
The spectrum of disease in chronic traumatic encephalopathy. Brain (2012) 5.10
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet (2006) 4.61
TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol (2010) 4.48
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci (2003) 3.67
Clinical presentation of chronic traumatic encephalopathy. Neurology (2013) 3.53
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem (2007) 3.35
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res (2002) 2.88
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol (2004) 2.50
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
A single-atom transistor. Nat Nanotechnol (2012) 2.35
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell (2013) 2.32
Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci (2006) 2.32
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22
Protective effects of NSAIDs on the development of Alzheimer disease. Neurology (2008) 2.21
Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A (2003) 2.21
Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc (2005) 2.21
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 2.07
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci (2002) 2.01
Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci (2007) 2.00
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol (2005) 1.95
Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A (2003) 1.92
Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci (2002) 1.92
Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci (2004) 1.92
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem (2005) 1.91
Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage (2006) 1.89
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88
SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol (2008) 1.84
Linking calcium to Abeta and Alzheimer's disease. Neuron (2008) 1.82
Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med (2005) 1.78
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. Cell Metab (2013) 1.74
Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol (2008) 1.71
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci (2006) 1.69
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci (2006) 1.66
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One (2011) 1.62
Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem (2003) 1.61
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci (2004) 1.54
Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem (2009) 1.53
Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem (2005) 1.52
Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium (2005) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51